
  
    
      
        Background_NNP
        Major_JJ histocompatibility_NN complex_JJ class_NN II_NNP molecules_NNS
        (_( MHCII_NNP )_) are_VBP heterodimeric_JJ transmembrane_NN glycoproteins_NNS that_WDT
        bind_NN antigenic_JJ peptides_NNS and_CC present_JJ such_JJ peptides_NNS to_TO CD_NNP 4_CD +_NN T_NN
        cells_NNS ._. Although_IN MHCII_NNP are_VBP not_RB expressed_VBN by_IN the_DT vast_JJ
        majority_NN of_IN studied_VBN mouse_NN and_CC human_JJ tumors_NNS ,_, CD_NNP 4_CD +_NN T_NN
        lymphocytes_NNS specific_JJ to_TO MHCII-restricted_NNP tumor_NN antigens_NNS
        have_VBP been_VBN found_VBN in_IN various_JJ cancers_NNS [_NN 1_CD ]_NN ._. Those_DT
        lymphocytes_NNS are_VBP believed_VBN to_TO be_VB generated_VBN 
        in_IN vivo_NN following_VBG the_DT recognition_NN of_IN
        MHCII-tumor_NNP peptide_NN complexes_NNS expressed_VBN by_IN host_NN antigen_NN
        presenting_VBG cells_NNS and_CC can_MD cause_VB regression_NN of_IN MHCII-negative_NNP
        tumors_NNS indirectly_RB ,_, via_IN secretion_NN of_IN cytokines_NNS such_JJ as_IN IL-_NNP 2_CD
        or_CC IFNg_NNP [_NN 2_CD ]_NN ._. The_DT released_VBN cytokines_NNS can_MD recruit_VB and_CC
        activate_VBP cytotoxic_JJ CD_NNP 8_CD +_NN T_NN lymphocytes_NNS and_CC /_NN or_CC accessory_JJ
        cells_NNS (_( eosinophills_NNS ,_, macrophages_NNS )_) which_WDT further_JJ mediate_VB
        tumor_NN destruction_NN ._.
        It_PRP has_VBZ been_VBN recently_RB appreciated_VBN that_IN sufficient_JJ
        concentrations_NNS of_IN secreted_JJ IFNg_NNP may_MD also_RB induce_VB susceptible_JJ
        tumors_NNS to_TO express_VB the_DT MHCII_NNP molecules_NNS ,_, potentially_RB leading_VBG
        to_TO increased_VB direct_JJ contact_NN with_IN CD_NNP 4_CD +_NN T_NN cells_NNS [_NN 3_CD ]_NN ._. Even_RB
        though_IN some_DT reports_NNS indicate_VBP that_DT tumor_NN sensitivity_NN to_TO IFNg_NNP
        is_VBZ not_RB required_VBN to_TO elicit_NN tumor_NN regression_NN [_NN 4_CD ]_NN ,_, it_PRP is_VBZ
        conceivable_JJ that_IN the_DT IFNg-induced_NNP MHCII_NNP expression_NN on_IN tumor_NN
        cells_NNS may_MD boost_VB the_DT effector_NN phase_NN of_IN antitumor_NN responses_NNS
        through_IN additional_JJ cytokine_NN release_NN or_CC direct_JJ tumor_NN
        eradication_NN by_IN CD_NNP 4_CD +_NN T_NN cells_NNS ._. Indeed_RB ,_, the_DT CD_NNP 4_CD +_NN T_NN cells_NNS that_WDT
        directly_RB destroy_VB MHCII-positive_NNP tumors_NNS were_VBD identified_VBN [_NN 5_CD
        ]_NN ._. In_IN the_DT clinic_NN ,_, the_DT expression_NN of_IN MHCII_NNP on_IN colorectal_NN
        carcinomas_NNS is_VBZ correlated_JJ with_IN more_RBR favourable_JJ prognosis_NN [_NN 6_CD
        ]_NN ._. Adoptive_NNP transfer_VB studies_NNS show_VBP that_IN 
        ex_FW vivo_NN activated_VBN CD_NNP 4_CD +_NN T_NN cells_NNS are_VBP
        able_JJ to_TO recognize_VB ,_, and_CC to_TO eliminate_VB ,_, MHCII-positive_NNP tumors_NNS
        either_CC by_IN themselves_PRP [_NN 7_CD ]_NN or_CC in_IN co-operation_JJ with_IN CD_NNP 8_CD +_NN T_NN
        cells_NNS [_NN 8_CD ]_NN ._. It_PRP has_VBZ been_VBN also_RB demonstrated_VBN that_IN the_DT
        increased_VBN MHCII_NNP expression_NN on_IN tumor_NN cells_NNS and_CC macrophages_NNS
        following_VBG treatment_NN with_IN IFNg_NNP 
        in_IN vivo_NN was_VBD associated_VBN with_IN enhanced_JJ
        efficacy_NN of_IN adoptive_JJ T_NN cell_NN therapy_NN in_IN a_DT mouse_NN model_NN of_IN
        metastatic_JJ sarcoma_NN [_NN 9_CD ]_NN ._.
        Unfortunately_RB ,_, the_DT induction_NN of_IN MHCII_NNP on_IN tumor_NN cells_NNS by_IN
        IFNg_NNP 
        in_IN vivo_NN is_VBZ difficult_JJ [_NN 10_CD ]_NN ._. In_IN
        fact_NN ,_, the_DT reported_VBD inducible_JJ tumors_NNS seem_VBP to_TO be_VB limited_VBN to_TO
        freshly_RB transplanted_VBN tumor_NN cells_NNS [_NN 9_CD 11_CD ]_NN or_CC malignant_JJ
        cells_NNS present_JJ in_IN the_DT ascitic_JJ fluid_JJ [_NN 12_CD ]_NN ._. Many_JJ tumors_NNS do_VBP
        not_RB express_VB MHCII_NNP after_IN treatment_NN with_IN recombinant_JJ IFNg_NNP 
        in_IN vitro_NN either_DT [_NN 13_CD ]_NN ._.
        Given_VBN the_DT role_NN that_IN MHCII_NNP may_MD play_VB in_IN tumor_NN immunity_NN ,_,
        further_JJ attempts_NNS to_TO restore_VB inducibility_NN in_IN IFNg-resistant_NNP
        tumors_NNS appear_VBP to_TO be_VB warranted_VBN ._. In_IN this_DT regard_NN ,_, several_JJ
        substances_NNS have_VBP recently_RB been_VBN tested_VBN using_VBG 
        in_IN vitro_NN models_NNS of_IN noninducible_JJ tumor_NN
        cell_NN lines_NNS ._. It_PRP was_VBD reported_VBN that_IN some_DT agents_NNS ,_, e_SYM ._. g_SYM ._. histone_NN
        deacetylase_NN inhibitors_NNS [_NN 14_CD ]_NN or_CC DNA_NNP methylation_NN inhibitors_NNS
        [_NN 15_CD ]_NN ,_, can_MD rescue_VB the_DT IFNg_NNP inducibility_NN of_IN MHCII_NNP in_IN
        cultured_JJ tumor_NN cells_NNS ._.
        In_IN this_DT study_NN ,_, we_PRP explored_JJ whether_IN the_DT effect_NN can_MD be_VB
        achieved_VBN by_IN yet_RB another_DT category_NN of_IN modulators_NNS ,_, the_DT PKC_NNP
        agonists_NNS ,_, chosen_VBN because_IN PKC_NNP has_VBZ been_VBN shown_VBN to_TO function_VB as_IN
        an_DT upstream_JJ regulator_NN of_IN the_DT MAPK_NNP pathway_NN [_NN 16_CD ]_NN that_WDT is_VBZ
        involved_VBN in_IN both_DT IFNg_NNP signal_NN transduction_NN [_NN 17_CD ]_NN and_CC
        regulation_NN of_IN gene_NN expression_NN [_NN 18_CD ]_NN ._.
        Specifically_RB ,_, the_DT influence_NN of_IN a_DT potent_JJ PKC_NNP activator_NN ,_,
        PMA_NNP ,_, and_CC clinically_RB tested_VBN drug_NN ,_, Bryostatin_NNP 1_CD ,_, on_IN the_DT
        IFNg-induced_NNP MHCII_NNP expression_NN in_IN several_JJ IFNg-resistant_NNP
        tumor_NN cell_NN lines_NNS was_VBD examined_VBN ._. Previously_RB ,_, PMA_NNP was_VBD shown_VBN to_TO
        augment_VB IFNg-mediated_NNP MHCII_NNP expression_NN in_IN MHCII-inducible_NNP
        tumor_NN cell_NN lines_NNS [_NN 19_CD 20_CD ]_NN ._. Here_RB ,_, we_PRP report_VBP that_IN the_DT
        presence_NN of_IN PMA_NNP in_IN tissue_NN culture_NN restores_NNS IFNg-dependent_NNP
        MHCII_NNP expression_NN in_IN the_DT poorly-responding_JJ LS_NNP 1034_CD colon_NN
        carcinoma_NN cell_NN line_NN but_CC fails_VBZ to_TO produce_VB this_DT effect_NN in_IN two_CD
        other_JJ IFNg-resistant_NNP cell_NN lines_NNS ,_, MSTO-_NNP 211_CD H_NNP mesothelioma_NN and_CC
        HepG_NNP 2_CD hepatocellular_NN carcinoma_NN ._. We_PRP also_RB show_VBP that_IN the_DT
        IFNg-dependent_NNP MHCII_NNP expression_NN in_IN LS_NNP 1034_CD cell_NN line_NN can_MD be_VB
        rescued_VBD by_IN clinically_RB acceptable_JJ concentrations_NNS of_IN
        Bryostatin_NNP 1_CD ._.
      
      
        Results_NNS
        
          Induction_NNP of_IN MHCII_NNP molecules_NNS by_IN IFNg_NNP in_IN four_CD
          different_JJ tumor_NN cell_NN lines_NNS
          We_PRP first_JJ compared_VBD the_DT induction_NN of_IN MHCII_NNP molecules_NNS in_IN
          SW_NNP 480_CD ,_, LS_NNP 1034_CD ,_, MSTO-_NNP 211_CD H_NNP and_CC HepG_NNP 2_CD tumor_NN cells_NNS in_IN
          response_NN to_TO different_JJ concentrations_NNS of_IN IFNg_NNP ._. MHCII_NNP
          antigens_NNS were_VBD initially_RB undetectable_JJ in_IN all_DT cell_NN lines_NNS
          tested_VBN ._. Incubation_NNP with_IN as_RB little_JJ as_IN 10_CD 2_CD IU_NNP /_NN ml_NN IFNg_NNP
          induced_VBD a_DT 10_CD -_: fold_VB increase_NN of_IN MHCII-specific_NNP fluorescence_NN
          in_IN SW_NNP 480_CD colon_NN carcinoma_NN cell_NN line_NN ._. In_IN contrast_NN ,_, LS_NNP 1034_CD
          demonstrated_VBN only_RB weak_JJ (_( 1_CD ._. 4_LS -_: to_TO 1_CD ._. 6_CD -_: fold_VB )_) increases_NNS in_IN
          level_NN of_IN MHCII_NNP ,_, and_CC remained_VBD weakly_RB inducible_JJ even_RB when_WRB
          concentration_NN of_IN IFNg_NNP was_VBD increased_VBN to_TO 10_CD 4_CD IU_NNP /_NN ml_NN (_( Figure_NN
          1_LS )_) ._. MSTO-_NNP 211_CD H_NNP ,_, mesothelioma_NN ,_, cell_NN line_NN also_RB showed_VBD a_DT weak_JJ
          induction_NN of_IN MHCII_NNP in_IN response_NN to_TO IFNg_NNP and_CC HepG_NNP 2_CD ,_,
          hepatocellular_NN carcinoma_NN ,_, was_VBD completely_RB non-inducible_JJ
          (_( data_NNS not_RB shown_VBN )_) ._.
          It_PRP should_MD be_VB noted_VBN ,_, however_RB ,_, that_IN we_PRP observed_VBD a_DT small_JJ
          population_NN of_IN LS_NNP 1034_CD cells_NNS (_( about_IN 5_CD -_: 10_CD %_NN of_IN all_DT cells_NNS )_)
          that_WDT demonstrated_VBD a_DT modest_JJ (_( 3_CD -_: to_TO 4_CD -_: fold_VB )_) increase_NN in_IN
          MHCII-specific_NNP fluorescence_NN after_IN incubation_NN with_IN 10_CD 2_CD -_: 10_CD
          4_CD IU_NNP /_NN ml_NN IFNg_NNP (_( data_NNS not_RB shown_VBN )_) ._. This_DT could_MD suggest_VB that_IN a_DT
          small_JJ subset_NN of_IN LS_NNP 1034_CD cells_NNS might_MD acquire_VB an_DT inducible_JJ
          phenotype_NN at_IN a_DT certain_JJ stage_NN of_IN cell_NN differentiation_NN ._.
        
        
          PMA_NNP rescues_VBZ IFNg_NNP inducibility_NN of_IN MHCII_NNP in_IN low_JJ
          responding_VBG LS_NNP 1034_CD colon_NN carcinoma_NN cell_NN line_NN
          We_PRP next_RB attempted_VBD to_TO restore_VB IFNg_NNP inducibility_NN of_IN
          MHCII_NNP in_IN poorly_RB responding_VBG tumor_NN cell_NN lines_NNS by_IN adding_VBG PKC_NNP
          agonist_NN PMA_NNP into_IN culture_NN medium_NN containing_VBG variable_JJ
          concentrations_NNS of_IN IFNg_NNP ._. PMA_NNP did_VBD not_RB improve_VB IFNg_NNP
          inducibility_NN of_IN MHCII_NNP in_IN MSTO-_NNP 211_CD H_NNP and_CC HepG_NNP 2_CD cell_NN lines_NNS
          (_( data_NNS not_RB shown_VBN )_) ._. The_DT LS_NNP 1034_CD cells_NNS ,_, on_IN the_DT other_JJ hand_NN ,_,
          demonstrated_VBD a_DT robust_JJ increase_NN in_IN MHCII_NNP expression_NN ._.
          The_DT magnitude_NN of_IN response_NN of_IN LS_NNP 1034_CD cells_NNS varied_VBD
          greatly_RB from_IN experiment_NN to_TO experiment_NN depending_VBG not_RB only_RB
          on_IN concentration_NN of_IN IFNg_NNP ,_, but_CC also_RB on_IN concentration_NN of_IN
          PMA_NNP and_CC even_RB on_IN type_NN of_IN the_DT PMA_NNP agent_NN (_( DMSO_NNP or_CC ethanol_NN )_) ._.
          Therefore_RB ,_, the_DT experiments_NNS were_VBD arranged_VBN in_IN a_DT factorial_NN
          design_NN for_IN accurate_JJ analysis_NN of_IN possible_JJ interactive_JJ
          effects_NNS ._. For_IN each_DT combination_NN of_IN treatments_NNS ,_, a_DT 3_CD -_: letter_NN
          alphanumeric_JJ code_NN was_VBD assigned_VBN (_( Table_NNP 1_LS )_) ._. Four_CD dose_NN
          levels_NNS of_IN IFNg_NNP combined_VBD with_IN 5_CD dose_NN levels_NNS of_IN PMA_NNP and_CC 2_CD
          dose_NN levels_NNS of_IN ethanol_NN generated_VBD 40_CD groups_NNS and_CC the_DT design_NN
          was_VBD replicated_VBN 4_CD times_NNS ._.
          The_DT results_NNS demonstrated_VBD a_DT substantial_JJ increase_NN in_IN
          MHCII_NNP expression_NN in_IN LS_NNP 1034_CD cell_NN line_NN following_VBG combined_VBN
          incubation_NN with_IN PMA_NNP and_CC IFNg_NNP (_( Figure_NN 2_LS )_) ._. Two-factor_NNP
          analysis_NN of_IN variance_NN revealed_VBD that_IN the_DT magnitude_NN of_IN MHCII_NNP
          induction_NN in_IN LS_NNP 1034_CD cells_NNS was_VBD almost_RB totally_RB determined_VBN
          by_IN concentration_NN of_IN IFNg_NNP (_( F_NN 
          2_CD ;_: 36_CD =_SYM 29_CD ._. 3_LS ,_, P_NN <_NN 10_CD -_: 6_CD )_) ._. Higher_JJR
          response_NN to_TO IFNg_NNP tended_VBD to_TO be_VB associated_VBN with_IN higher_JJR
          concentration_NN of_IN PMA_NNP in_IN some_DT experiments_NNS ,_, but_CC the_DT overall_JJ
          effect_NN of_IN PMA_NNP did_VBD not_RB reach_VB a_DT commonly_RB accepted_VBN level_NN of_IN
          significance_NN (_( F_NN 
          3_CD ;_: 36_CD =_SYM 1_CD ._. 9_CD ,_, P_NN =_SYM 0_CD ._. 14_CD )_) ._. Interestingly_RB ,_,
          the_DT effect_NN of_IN PMA_NNP did_VBD reach_VB significance_NN in_IN cultures_NNS
          supplemented_JJ with_IN 172_CD mM_NN ethanol_NN (_( F_NN 
          3_CD ;_: 36_CD =_SYM 3_CD ._. 0_CD ,_, P_NN =_SYM 0_CD ._. 043_CD ;_: groups_NNS 09_CD b_SYM →_NN 12_CD b_SYM ,_,
          15_CD b_SYM →_NN 18_CD b_SYM ,_, 21_CD b_SYM →_NN 24_CD b_SYM )_) ._. No_DT interaction_NN effect_NN between_IN PMA_NNP and_CC
          IFNg_NNP was_VBD found_VBN (_( F_NN 
          6_CD ;_: 36_CD =_SYM 0_CD ._. 14_CD ,_, P_NN =_SYM 0_CD ._. 99_CD )_) ._.
          Since_IN there_EX were_VBD no_DT 2_CD -_: factor_NN interactions_NNS ,_, several_JJ
          single-factor_JJ groups_NNS were_VBD added_VBN ,_, and_CC data_NNS were_VBD
          re-analysed_JJ by_IN using_VBG one-way_JJ ANOVA_NNP ._. Different_JJ
          combinations_NNS of_IN PMA_NNP and_CC IFNg_NNP were_VBD compared_VBN to_TO the_DT highest_JJS
          dose_NN of_IN IFNg_NNP used_VBD without_IN PMA_NNP (_( group_NN 20_CD a_DT or_CC 20_CD b_SYM )_) ._.
          Multiple_NNP comparisons_NNS were_VBD made_VBN using_VBG Tukey_NNP 's_POS HSD_NNP test_NN and_CC
          Scheffe_NNP 's_POS test_NN (_( the_DT latter_NN test_NN is_VBZ more_RBR conservative_JJ )_) ._.
          Results_NNS demonstrate_VBP that_IN the_DT expression_NN level_NN of_IN MHCII_NNP
          reached_VBD a_DT plateau_NN at_IN 10_CD 3_CD IU_NNP /_NN ml_NN IFNg_NNP in_IN the_DT presence_NN of_IN 10_CD
          2_CD -_: 10_CD 4_CD ng_NN /_NN ml_NN PMA_NNP and_CC 172_CD mM_NN ethanol_NN ._. Further_RB increases_VBZ in_IN
          concentration_NN of_IN IFNg_NNP (_( to_TO 10_CD 4_CD IU_NNP /_NN ml_NN )_) did_VBD not_RB result_VB in_IN
          statistically_RB significant_JJ increases_NNS of_IN MHCII_NNP expression_NN
          (_( Figure_NN 2_CD B_NNP )_) ._.
          Figure_NN 2_CD also_RB demonstrates_VBZ that_DT ethanol_NN was_VBD totally_RB
          inactive_JJ alone_RB (_( compare_VB group_NN 20_CD a_DT vs_NNS ._. 20_CD b_SYM )_) but_CC it_PRP
          significantly_RB improved_VBD the_DT MHCII_NNP induction_NN in_IN the_DT
          presence_NN of_IN PMA_NNP ._. Because_IN of_IN variation_NN between_IN
          experiments_NNS ,_, the_DT effect_NN of_IN EtOH_NNP could_MD not_RB be_VB seen_VBN clearly_RB
          in_IN Figure_NN 2_CD ._. For_IN that_DT reason_NN ,_, pair-wise_JJ comparisons_NNS were_VBD
          made_VBN between_IN cell_NN cultures_NNS incubated_JJ either_CC with_IN PMA_NNP or_CC
          with_IN a_DT combination_NN of_IN PMA_NNP and_CC EtOH_NNP ._. Specifically_RB ,_, group_NN
          09_CD a_DT was_VBD compared_VBN to_TO group_VB 09_CD b_SYM ,_, etc_FW ._. Data_NNP shown_VBN in_IN Figure_NN
          3_CD confirm_VB that_IN EtOH_NNP significantly_RB improved_VBD PMA-potentiated_NNP
          response_NN to_TO IFNg_NNP ._. Linear_NNP regression_NN analysis_NN also_RB
          revealed_VBD that_IN the_DT effect_NN of_IN ethanol_NN was_VBD more_RBR pronounced_JJ
          at_IN 10_CD 2_CD IU_NNP /_NN ml_NN IFNg_NNP ._.
          Taken_VBN together_RB ,_, the_DT above_JJ results_NNS showed_VBD a_DT strong_JJ
          potentiating_VBG effect_NN of_IN PMA_NNP on_IN IFNg-induced_NNP HLA-DR_NNP
          expression_NN in_IN LS_NNP 1034_CD cell_NN line_NN and_CC no_DT changes_NNS in_IN two_CD
          other_JJ poorly_RB inducible_JJ cell_NN lines_NNS ._.
        
        
          Expression_NNP levels_NNS of_IN IFNg_NNP receptors_NNS in_IN four_CD
          different_JJ tumor_NN cell_NN lines_NNS do_VBP not_RB change_VB following_VBG
          incubation_NN with_IN PMA_NNP
          It_PRP has_VBZ been_VBN previously_RB shown_VBN that_IN potentiating_VBG effect_NN
          of_IN phorbol_NN esters_NNS on_IN IFNg-dependent_NNP MHCII_NNP induction_NN in_IN
          THP-_NNP 1_CD monocytic_JJ cell_NN line_NN was_VBD associated_VBN with_IN the_DT
          increase_NN in_IN synthesis_NN of_IN IFNg_NNP receptors_NNS [_NN 19_CD ]_NN ._. For_IN that_DT
          reason_NN ,_, we_PRP questioned_VBD whether_IN PMA_NNP could_MD produce_VB similar_JJ
          changes_NNS in_IN LS_NNP 1034_CD colon_NN carcinoma_NN cells_NNS ._. We_PRP compared_VBD the_DT
          expression_NN of_IN alpha_NN and_CC beta_NN chains_NNS of_IN IFNg_NNP receptor_NN
          (_( IFNgR_NNP 1_CD and_CC IFNgR_NNP 2_LS )_) in_IN LS_NNP 1034_CD carcinoma_NN and_CC three_CD other_JJ
          tumor_NN cell_NN lines_NNS before_IN and_CC after_IN 48_CD hr_NN incubation_NN with_IN
          10_CD 3_CD ng_NN /_NN ml_NN PMA_NNP and_CC 172_CD mM_NN ethanol_NN ._. Results_NNS ,_, plotted_VBD in_IN
          Figure_NN 4_CD ,_, show_NN that_IN untreated_JJ and_CC PMA-treated_NNP tumor_NN cells_NNS
          express_VBP about_IN the_DT same_JJ levels_NNS of_IN IFNgR_NNP 1_CD and_CC IFNgR_NNP 2_CD ._.
          Moreover_RB ,_, the_DT level_NN of_IN IFNgR_NNP 1_CD in_IN HepG_NNP 2_CD cells_NNS actually_RB
          drops_VBZ after_IN exposure_NN to_TO PMA_NNP ._. Therefore_RB ,_, we_PRP conclude_VBP that_IN
          it_PRP is_VBZ unlikely_JJ that_IN PMA_NNP action_NN in_IN LS_NNP 1034_CD carcinoma_NN is_VBZ
          mediated_JJ through_IN increased_VBN synthesis_NN of_IN IFNg_NNP
          receptors_NNS ._.
        
        
          Expression_NNP of_IN the_DT retinoblastoma_NN protein_NN is_VBZ not_RB
          lost_VBN in_IN LS_NNP 1034_CD ,_, MSTO-_NNP 211_CD H_NNP and_CC HepG_NNP 2_CD cell_NN lines_NNS
          A_DT substantial_JJ percentage_NN of_IN human_JJ tumors_NNS lose_VBP the_DT
          expression_NN of_IN the_DT retinoblastoma_NN tumor_NN suppressor_NN protein_NN
          (_( Rb_NNP )_) ,_, important_JJ as_IN a_DT necessary_JJ condition_NN for_IN
          IFNg-mediated_NNP induction_NN of_IN MHCII_NNP [_NN 21_CD ]_NN ._. Therefore_RB ,_, we_PRP
          wished_VBD to_TO determine_VB whether_IN the_DT poor_JJ IFNg_NNP inducibility_NN of_IN
          MHCII_NNP in_IN LS_NNP 1034_CD ,_, MSTO-_NNP 211_CD H_NNP and_CC HepG_NNP 2_CD cell_NN lines_NNS could_MD be_VB
          explained_VBN by_IN the_DT loss_NN of_IN Rb_NNP ._. Immunofluorescent_NNP staining_VBG
          with_IN a_DT Rb-specific_NNP mAb_NN (_( clone_NN G_NNP 3_CD -_: 245_CD )_) demonstrated_VBN that_IN
          all_DT cell_NN lines_NNS tested_VBN expressed_VBD Rb_NNP (_( Figure_NN 5_LS )_) ._.
          A_DT closer_JJR look_NN at_IN Figure_NN 5_CD reveals_VBZ that_IN the_DT 4_CD cell_NN lines_NNS
          can_MD be_VB ranked_VBN according_VBG to_TO their_PRP$ Rb_NNP contents_NNS in_IN the_DT
          following_JJ order_NN :_: SW_NNP 480_CD >_NN LS_NNP 1034_CD >_NN MSTO-_NNP 211_CD H_NNP >_NN
          HepG_NNP 2_CD ._. This_DT ranking_NN would_MD be_VB valid_JJ only_RB if_IN fluorescence_NN
          intensity_NN correlates_NNS closely_RB with_IN the_DT absolute_JJ contents_NNS
          of_IN Rb_NNP protein_NN per_IN cell_NN ._. However_RB ,_, this_DT may_MD not_RB always_RB be_VB
          the_DT case_NN ._. For_IN example_NN ,_, the_DT number_NN of_IN epitopes_NNS recognized_VBN
          by_IN G_NNP 3_CD -_: 245_CD mAb_NN may_MD be_VB reduced_VBN if_IN tumor_NN cells_NNS express_VBP viral_JJ
          oncoproteins_NNS that_WDT bind_NN and_CC inactivate_NN Rb_NNP [_NN 22_CD ]_NN ._.
          It_PRP is_VBZ important_JJ to_TO note_VB that_IN certain_JJ mutations_NNS greatly_RB
          reduce_VBP transport_NN of_IN newly_RB synthesized_JJ Rb_NNP molecules_NNS into_IN
          the_DT nucleus_NN where_WRB Rb_NNP performs_VBZ its_PRP$ function_NN [_NN 23_CD ]_NN ._. As_IN
          the_DT flow_NN cytometry_NN protocol_NN does_VBZ not_RB allow_VB us_PRP to_TO
          discriminate_JJ between_IN cytoplasmic_JJ and_CC nuclear_JJ staining_VBG ,_,
          the_DT question_NN about_IN the_DT presence_NN of_IN functional_JJ Rb_NNP protein_NN
          in_IN the_DT examined_VBN cell_NN lines_NNS remains_VBZ open_JJ ._.
        
        
          Effect_NN of_IN protein_NN kinase_NN inhibitors_NNS on_IN
          physiological_JJ and_CC PMA-potentiated_NNP response_NN to_TO IFNg_NNP
          The_DT discovery_NN of_IN novel_NN "_'' non-kinase_JJ "_'' phorbol_NN ester_NN
          receptors_NNS challenges_VBZ the_DT use_NN of_IN phorbol_NN esters_NNS as_IN
          selective_JJ PKC_NNP activators_NNS [_NN 24_CD ]_NN ._. Therefore_RB ,_, we_PRP were_VBD
          interested_JJ in_IN whether_IN a_DT member_NN of_IN the_DT PKC_NNP family_NN mediated_JJ
          the_DT effect_NN of_IN PMA_NNP in_IN LS_NNP 1034_CD cells_NNS or_CC whether_IN some_DT other_JJ
          proteins_NNS could_MD also_RB be_VB involved_VBN ._. Specifically_RB ,_, we_PRP
          investigated_VBD whether_IN two_CD inhibitors_NNS ,_, staurosporine_NN and_CC GF_NNP
          109203_CD X_NNP ,_, could_MD abrogate_NN PMA-potentiated_NNP response_NN of_IN
          LS_NNP 1034_CD cells_NNS to_TO IFNg_NNP ._. Staurosporine_NNP is_VBZ a_DT wide-spectrum_JJ
          kinase_NN inhibitor_NN and_CC its_PRP$ specificity_NN for_IN PKC_NNP isoforms_NNS is_VBZ
          limited_VBN to_TO the_DT 0_CD ._. 1_CD -_: 1_CD nanomolar_NN range_NN ._. In_IN the_DT 10_CD -_: 100_CD nM_NN
          range_NN ,_, staurosporine_NN inhibits_NNS more_JJR than_IN 20_CD different_JJ
          kinases_NNS [_NN 25_CD ]_NN ._.
          Data_NNP shown_VBN in_IN Figure_NN 6_CD demonstrate_VB that_DT staurosporine_NN
          caused_VBN about_IN a_DT 50_CD %_NN inhibition_NN of_IN PMA-potentiated_NNP response_NN
          in_IN LS_NNP 1034_CD cells_NNS at_IN a_DT concentration_NN of_IN 10_CD nM_NN ._. Complete_JJ
          inhibition_NN occurred_VBD at_IN 100_CD nM_NN ._. A_DT much_RB higher_JJR
          concentration_NN of_IN GF_NNP 109203_CD X_NNP was_VBD required_VBN to_TO completely_RB
          suppress_VB PMA-potentiated_NNP response_NN in_IN LS_NNP 1034_CD cells_NNS ._.
          Physiological_NNP IFNg_NNP response_NN in_IN SW_NNP 480_CD colon_NN carcinoma_NN
          cells_NNS was_VBD resistant_JJ to_TO inhibition_NN with_IN 1_CD μM_NN GF_NNP 109203_CD X_NNP
          and_CC was_VBD suppressed_VBN only_RB when_WRB staurosporine_NN concentration_NN
          was_VBD increased_VBN to_TO 1_CD μM_NN ._. We_PRP conclude_VBP that_IN the_DT PMA_NNP effect_NN in_IN
          LS_NNP 1034_CD cell_NN line_NN is_VBZ most_RBS likely_JJ mediated_JJ by_IN a_DT PKC_NNP
          isoenzyme_NN but_CC other_JJ protein_NN kinases_NNS that_WDT are_VBP sensitive_JJ to_TO
          inhibition_NN with_IN 1_CD μM_NN GF_NNP 109203_CD X_NNP ._.
        
        
          Bryostatin_NNP 1_CD rescues_VBZ IFNg_NNP inducibility_NN of_IN MHCII_NNP in_IN
          LS_NNP 1034_CD colon_NN carcinoma_NN cells_NNS
          To_TO evaluate_VB potential_JJ clinical_JJ implications_NNS of_IN our_PRP$
          findings_NNS ,_, we_PRP asked_VBD whether_IN the_DT IFNg-dependent_NNP MHCII_NNP
          expression_NN in_IN LS_NNP 1034_CD cells_NNS could_MD be_VB restored_VBN by_IN
          clinically_RB achievable_JJ concentrations_NNS of_IN PKC_NNP agonists_NNS ._.
          Bryostatin_NNP 1_CD is_VBZ a_DT potent_JJ PKC_NNP activator_NN that_WDT has_VBZ undergone_VBN
          extensive_JJ clinical_JJ testing_NN for_IN the_DT treatment_NN of_IN
          hematological_JJ malignancies_NNS and_CC solid_JJ tumors_NNS [_NN 27_CD ]_NN ._.
          Animal_NNP studies_NNS show_VBP that_IN the_DT concentration_NN of_IN Bryostatin_NNP
          1_CD in_IN various_JJ tissues_NNS after_IN a_DT single_JJ intraveneous_JJ
          injection_NN stays_VBZ in_IN a_DT range_NN of_IN 10_CD -_: 50_CD ng_NN /_NN g_SYM for_IN a_DT period_NN of_IN
          more_JJR than_IN 72_CD hr_NN [_NN 28_CD ]_NN ._.
          Data_NNP ,_, plotted_VBD in_IN Figure_NN 7_CD ,_, demonstrate_VBP that_IN 10_CD ng_NN /_NN ml_NN
          Bryostatin_NNP added_VBD into_IN the_DT culture_NN medium_NN containing_VBG 10_CD
          2_CD -_: 10_CD 3_CD IU_NNP /_NN ml_NN IFNg_NNP induced_VBD a_DT 5_CD -_: to_TO 6_CD -_: fold_VB increase_NN in_IN
          levels_NNS of_IN MHCII_NNP expression_NN ._. The_DT potentiating_VBG effect_NN of_IN
          Bryostatin_NNP first_JJ becomes_VBZ noticeable_JJ at_IN 1_CD ng_NN /_NN ml_NN and_CC then_RB
          reaches_VBZ a_DT plateau_NN at_IN 10_CD -_: 100_CD ng_NN /_NN ml_NN ._. At_IN low_JJ concentration_NN
          of_IN IFNg_NNP (_( 10_CD 2_CD IU_NNP /_NN ml_NN )_) ,_, the_DT effect_NN of_IN Bryostatin_NNP was_VBD
          comparable_JJ to_TO that_DT of_IN PMA_NNP ._. At_IN a_DT higher_JJR concentration_NN of_IN
          IFNg_NNP (_( 10_CD 3_CD IU_NNP /_NN ml_NN )_) ,_, however_RB ,_, PMA_NNP was_VBD much_RB more_RBR effective_JJ ._.
          This_DT may_MD suggest_VB that_IN either_DT the_DT two_CD PKC_NNP activators_NNS act_VBP
          through_IN different_JJ isoforms_NNS of_IN PKC_NNP or_CC PMA_NNP also_RB activates_NNS
          enzymes_NNS outside_IN the_DT PKC_NNP family_NN such_JJ as_IN MAPK_NNP [_NN 18_CD ]_NN ._.
          Whatever_WDT the_DT mechanism_NN ,_, it_PRP appears_VBZ possible_JJ to_TO restore_VB
          the_DT IFNg-dependent_NNP MHCII_NNP expression_NN in_IN LS_NNP 1034_CD cell_NN line_NN
          by_IN clinically_RB acceptable_JJ concentrations_NNS of_IN Bryostatin_NNP
          1_CD ._.
        
      
      
        Discussion_NNP
        The_DT effect_NN of_IN PKC_NNP activators_NNS PMA_NNP and_CC Bryostatin_NNP 1_CD on_IN
        IFNg_NNP inducibility_NN of_IN MHCII_NNP in_IN three_CD resistant_JJ tumor_NN cell_NN
        lines_NNS of_IN different_JJ histological_JJ origin_NN has_VBZ been_VBN examined_VBN ._.
        We_PRP found_VBD that_IN PKC_NNP activators_NNS rescued_VBD high_JJ levels_NNS of_IN MHCII_NNP
        expression_NN in_IN colon_NN carcinoma_NN cells_NNS and_CC failed_VBD to_TO do_VB so_RB in_IN
        mesothelioma_NN and_CC hepatocellular_NN carcinoma_NN cells_NNS ._. A_DT poor_JJ
        response_NN of_IN tumor_NN cells_NNS to_TO IFNg_NNP is_VBZ in_IN agreement_NN with_IN
        previous_JJ observations_NNS that_IN many_JJ tumors_NNS acquire_VB such_JJ
        resistance_NN upon_IN malignant_JJ transformation_NN ,_, possibly_RB
        important_JJ as_IN a_DT mechanism_NN of_IN tumor_NN escape_NN from_IN immune_JJ
        surveillance_NN [_NN 29_CD ]_NN ._. The_DT nature_NN of_IN this_DT phenomenon_NN is_VBZ
        complex_JJ ,_, and_CC multiple_JJ defects_NNS that_WDT can_MD prevent_VB IFNg_NNP
        responses_NNS in_IN tumor_NN lines_NNS have_VBP been_VBN described_VBN ._.
        Most_JJS frequently_RB ,_, poor_NNP MHCII_NNP inducibility_NN in_IN response_NN to_TO
        IFNg_NNP has_VBZ been_VBN attributed_VBN to_TO alterations_NNS in_IN the_DT IFNg_NNP
        signalling_VBG pathway_NN and_CC epigenetic_JJ silencing_VBG of_IN gene_NN
        expression_NN (_( reviewed_VBN in_IN Ref_NNP [_NN 13_CD ]_NN )_) ._. The_DT cascade_NN of_IN IFNg_NNP
        signalling_VBG events_NNS leading_VBG to_TO transcription_NN activation_NN of_IN
        MHCII_NNP genes_NNS has_VBZ been_VBN characterized_VBN in_IN great_JJ detail_NN
        (_( reviewed_VBN in_IN Ref_NNP [_NN 30_CD ]_NN )_) ._. Binding_NNP of_IN IFNg_NNP to_TO its_PRP$ receptor_NN
        results_NNS in_IN JAK-mediated_NNP phosphorylation_NN of_IN STAT_NNP 1_CD on_IN
        Tyrosine_NNP 701_CD ._. In_IN addition_NN ,_, IFNg_NNP interaction_NN with_IN the_DT
        receptor_NN leads_VBZ to_TO p_NN 38_CD MAPK-mediated_NNP phosphorylation_NN of_IN STAT_NNP 1_CD
        on_IN Serine_NNP 727_NNP [_NN 17_CD ]_NN ._. The_DT phosphorylated_JJ STAT_NNP 1_CD dimerizes_NNS
        and_CC translocates_NNS into_IN the_DT nucleus_NN where_WRB it_PRP activates_NNS
        transcription_NN of_IN several_JJ other_JJ factors_NNS including_VBG CIITA_NNP [_NN 31_CD
        ]_NN ._. Although_IN the_DT results_NNS of_IN this_DT study_NN do_VBP not_RB allow_VB us_PRP to_TO
        describe_VB the_DT exact_JJ mechanism_NN of_IN PMA_NNP involvement_NN in_IN IFNg_NNP
        signalling_VBG in_IN LS_NNP 1034_CD cell_NN ,_, at_IN least_JJS two_CD non-mutually_JJ
        exclusive_JJ scenarios_NNS can_MD be_VB hypothesized_VBN :_:
        1_LS ._. PMA_NNP could_MD act_VB through_IN the_DT JAK-STAT_NNP signalling_VBG
        pathway_NN ._. It_PRP has_VBZ been_VBN established_VBN that_IN ,_, to_TO achieve_VB its_PRP$
        maximal_NN transcriptional_NN activity_NN ,_, STAT_NNP 1_CD must_MD be_VB
        phosphorylated_JJ on_IN both_DT Tyr_NNP 701_CD and_CC Ser_NNP 727_NNP [_NN 32_CD ]_NN ._.
        Phosphorylation_NNP of_IN STAT_NNP 1_CD on_IN Ser_NNP 727_NNP occurs_VBZ in_IN response_NN to_TO
        LPS_NNP ,_, UV_NNP irradiation_NN and_CC other_JJ agents_NNS that_WDT activate_VBP the_DT
        p_NN 38_CD MAPK_NNP pathway_NN [_NN 33_CD ]_NN ._. As_IN phorbol_NN esters_NNS can_MD also_RB
        stimulate_VB the_DT MAPK_NNP cascade_NN through_IN activation_NN of_IN PKC_NNP [_NN 34_CD ]_NN
        ,_, it_PRP is_VBZ tempting_JJ to_TO speculate_VB that_WDT combined_VBD treatment_NN of_IN
        cells_NNS with_IN PMA_NNP and_CC IFNg_NNP could_MD increase_VB the_DT pool_NN of_IN STAT_NNP 1_CD
        molecules_NNS phosphorylated_JJ on_IN both_DT Tyr_NNP 701_CD and_CC Ser_NNP 727_NNP ._. This_DT
        effect_NN is_VBZ most_RBS likely_JJ mediated_JJ by_IN PKC-delta_NNP isoenzyme_NN as_IN
        this_DT particular_JJ PKC_NNP isoform_NN appears_VBZ to_TO be_VB critical_JJ for_IN
        phosphorylation_NN of_IN STAT_NNP 1_CD on_IN Ser_NNP 727_NNP and_CC activation_NN of_IN
        p_NN 38_CD MAPK_NNP [_NN 16_CD ]_NN ._.
        2_LS ._. Alternatively_RB ,_, PMA_NNP treatment_NN could_MD initiate_VB a_DT cascade_NN
        of_IN protein_NN phosphorylation_NN leading_VBG to_TO the_DT increase_NN in_IN
        transcriptional_NN activity_NN of_IN chromatin_NN at_IN the_DT type_NN IV_NNP
        promoter_NN of_IN CIITA_NNP and_CC /_NN or_CC promoter_NN of_IN MHCII_NNP genes_NNS ._.
        Expression_NNP of_IN many_JJ genes_NNS can_MD be_VB modified_VBN by_IN treatment_NN with_IN
        agents_NNS acting_VBG at_IN the_DT level_NN of_IN enzymes_NNS and_CC nuclear_JJ receptors_NNS
        that_WDT modify_VB transcriptional_NN activity_NN of_IN chromatin_NN ._. Thus_RB ,_,
        histone_NN deacetylase_NN inhibitors_NNS -_: Butyrate_NNP and_CC Trichostatin_NNP
        A_DT -_: can_MD rescue_VB MHCII-inducibility_NNP in_IN bladder_NN carcinoma_NN
        cells_NNS [_NN 14_CD ]_NN and_CC restore_VB constitutive_JJ MHCII_NNP expression_NN in_IN
        plasmacytoma_NN cells_NNS [_NN 35_CD ]_NN ._. In_IN addition_NN to_TO acetylation_NN ,_,
        transcriptional_NN activity_NN of_IN chromatin_NN is_VBZ also_RB regulated_VBN
        through_IN phosphorylation_NN (_( reviewed_VBN in_IN Ref_NNP ._. [_NN 36_CD ]_NN )_) ._. It_PRP has_VBZ
        been_VBN shown_VBN that_DT treatment_NN of_IN cells_NNS with_IN phorbol_NN esters_NNS
        leads_VBZ to_TO accumulation_NN of_IN phosphorylated_JJ H_NNP 3_CD histones_NNS [_NN 37_CD ]_NN
        ._. Therefore_RB ,_, it_PRP seems_VBZ possible_JJ that_IN in_IN LS_NNP 1034_CD cells_NNS PMA_NNP
        could_MD enhance_VB transcriptional_NN activity_NN of_IN chromatin_NN at_IN
        promoters_NNS of_IN MHCII_NNP and_CC /_NN or_CC CIITA_NNP genes_NNS ._. This_DT possibility_NN
        appears_VBZ particularly_RB important_JJ since_IN the_DT specific_JJ lack_NN of_IN
        CIITA_NNP inducibility_NN was_VBD cited_VBN as_IN the_DT most_RBS common_JJ basis_NN for_IN
        lack_NN of_IN IFNg-induced_NNP MHCII_NNP expression_NN among_IN Rb-positive_NNP
        human_JJ tumor_NN lines_NNS [_NN 13_CD 21_CD ]_NN ._.
        Another_DT reported_VBN mechanism_NN of_IN IFNg_NNP resistance_NN in_IN tumor_NN
        cells_NNS is_VBZ associated_VBN with_IN down-regulation_JJ of_IN IFNg-receptors_NNP
        [_NN 38_CD ]_NN ._. The_DT relevance_NN of_IN this_DT mechanism_NN to_TO MHCII_NNP
        inducibility_NN was_VBD recently_RB supported_VBN by_IN the_DT evidence_NN that_IN
        PMA_NNP is_VBZ able_JJ to_TO enhance_VB IFNg-dependent_NNP MHCII_NNP expression_NN in_IN
        THP-_NNP 1_CD human_JJ leukemia_NN cells_NNS through_IN the_DT up-regulation_JJ of_IN
        IFNg_NNP receptors_NNS [_NN 19_CD ]_NN ._. In_IN our_PRP$ experiments_NNS ,_, however_RB ,_, the_DT
        incubation_NN of_IN LS_NNP 1034_CD cells_NNS with_IN PMA_NNP and_CC ethanol_NN did_VBD not_RB
        lead_VB to_TO any_DT changes_NNS in_IN IFNgR_NNP expression_NN as_IN determined_VBN by_IN
        flow_NN cytometry_NN (_( Figure_NN 4_LS )_) ._. Therefore_RB ,_, it_PRP is_VBZ unlikely_JJ that_IN
        up-regulated_JJ IFNgR_NNP contributed_VBD to_TO the_DT phenomena_NNS reported_VBD
        here_RB ._. It_PRP should_MD be_VB emphasized_VBN that_IN we_PRP determined_VBD the_DT
        expression_NN of_IN both_DT IFNgR_NNP 1_CD and_CC IFNgR_NNP 2_CD receptor_NN subunits_NNS
        since_IN it_PRP has_VBZ been_VBN shown_VBN that_IN ,_, in_IN certain_JJ experimental_JJ
        systems_NNS ,_, an_DT IFNg_NNP resistance_NN was_VBD due_JJ to_TO a_DT lack_NN of_IN cellular_JJ
        expression_NN of_IN IFNgR_NNP 2_CD chain_NN alone_RB [_NN 39_CD ]_NN ._.
        We_PRP also_RB found_VBD that_IN the_DT effect_NN of_IN PMA_NNP in_IN LS_NNP 1034_CD cells_NNS can_MD
        be_VB significantly_RB augmented_JJ by_IN co-incubation_JJ with_IN 172_CD mM_NN
        ethanol_NN ._. In_IN certain_JJ types_NNS of_IN tissues_NNS ,_, ethanol_NN has_VBZ been_VBN
        shown_VBN to_TO induce_VB membrane_NN translocation_NN of_IN PKC_NNP isoforms_NNS
        through_IN activation_NN of_IN phospholipase_NN A_DT and_CC release_NN of_IN
        diacylglycerol_NN [_NN 40_CD ]_NN ._. This_DT mechanism_NN ,_, however_RB ,_, does_VBZ not_RB
        appear_VB to_TO be_VB significant_JJ in_IN our_PRP$ case_NN as_IN ethanol_NN without_IN PMA_NNP
        failed_VBD to_TO potentiate_NN IFNg-induced_NNP MHCII_NNP expression_NN in_IN
        LS_NNP 1034_CD cells_NNS ._. Alternatively_RB ,_, ethanol_NN can_MD modulate_VBP the_DT
        activity_NN of_IN mitogen-_NN and_CC stress-activated_JJ kinase_NN cascades_NNS ._.
        It_PRP has_VBZ been_VBN shown_VBN that_IN hepatocytes_NNS exposed_VBN to_TO 100_CD mM_NN
        ethanol_NN for_IN 16_CD hr_NN have_VBP a_DT higher_JJR activity_NN of_IN p_NN 38_CD MAPK_NNP induced_VBN
        by_IN EGF_NNP treatment_NN [_NN 41_CD ]_NN ._. If_IN in_IN our_PRP$ experiments_NNS PMA_NNP did_VBD act_NN
        through_IN Ser_NNP 727_NNP phosphorylation_NN of_IN STAT_NNP 1_CD ,_, the_DT potentiating_VBG
        effect_NN of_IN ethanol_NN can_MD possibly_RB be_VB explained_VBN by_IN its_PRP$ ability_NN
        to_TO stimulate_VB the_DT MAPK_NNP kinase_NN cascade_NN ._.
        It_PRP remains_VBZ to_TO be_VB determined_VBN whether_IN the_DT restoration_NN of_IN
        IFNg-induced_NNP MHCII_NNP expression_NN by_IN PMA_NNP is_VBZ unique_JJ to_TO LS_NNP 1034_CD
        cells_NNS ._. A_DT potentiating_VBG effect_NN of_IN PMA_NNP has_VBZ been_VBN reported_VBN in_IN
        thyroid_NN carcinoma_NN cells_NNS [_NN 20_CD ]_NN but_CC ,_, in_IN contrast_NN to_TO LS_NNP 1034_CD
        cells_NNS ,_, normal_JJ IFNg_NNP response_NN in_IN those_DT cells_NNS was_VBD only_RB
        partially_RB lost_VBD as_IN a_DT result_NN of_IN malignant_JJ transformation_NN ._.
        Whether_IN or_CC not_RB this_DT phenomenon_NN may_MD be_VB reproduced_VBD with_IN other_JJ
        IFNg-resistant_NNP colon_NN carcinoma_NN cell_NN lines_NNS is_VBZ of_IN particular_JJ
        interest_NN ,_, since_IN colonic_JJ epithelium_NN is_VBZ physiologically_RB
        exposed_VBN to_TO PKC_NNP activators_NNS that_WDT enhance_VB cytokine_NN signalling_VBG
        in_IN enterocytes_NNS during_IN inflammatory_JJ responses_NNS within_IN the_DT
        intestinal_NN mucosa_NN [_NN 42_CD ]_NN ._.
        It_PRP is_VBZ well_RB established_VBN that_IN ,_, besides_IN the_DT MHCII_NNP
        molecules_NNS ,_, IFNg_NNP can_MD induce_VB susceptible_JJ tumors_NNS to_TO upregulate_NN
        the_DT expression_NN of_IN MHC_NNP class_NN I_PRP antigens_NNS [_NN 43_CD ]_NN ,_, tumor_NN
        associated_VBN antigens_NNS [_NN 44_CD ]_NN ,_, costimulatory_NN molecules_NNS [_NN 45_CD ]_NN
        ,_, and_CC heat_NN shock_NN proteins_NNS [_NN 46_CD ]_NN ._. In_IN addition_NN ,_, IFNg_NNP may_MD
        have_VB antimetabolic_JJ and_CC antiproliferative_JJ influence_NN on_IN
        certain_JJ types_NNS of_IN tumor_NN cells_NNS [_NN 47_CD ]_NN ._. It_PRP has_VBZ also_RB been_VBN
        suggested_VBN that_IN IFNg_NNP may_MD cause_VB responding_VBG tumor_NN cells_NNS to_TO
        secrete_NN angiogenesis_NNS inhibitors_NNS [_NN 48_CD ]_NN ._. As_IN it_PRP is_VBZ not_RB known_VBN
        which_WDT of_IN those_DT IFNg_NNP effects_NNS are_VBP missing_VBG or_CC restored_VBN by_IN PMA_NNP
        in_IN LS_NNP 1034_CD cells_NNS ,_, a_DT thorough_JJ evaluation_NN of_IN the_DT possible_JJ
        clinical_JJ implications_NNS of_IN our_PRP$ 
        in_IN vitro_NN findings_NNS is_VBZ quite_RB difficult_JJ ._.
        However_RB ,_, if_IN clinically_RB tested_VBN PKC_NNP agonists_NNS such_JJ as_IN
        Bryostatin_NNP 1_CD are_VBP able_JJ to_TO rescue_VB the_DT IFNg-induced_NNP MHCII_NNP
        expression_NN within_IN the_DT tumor_NN bed_NN ,_, it_PRP might_MD be_VB appropriate_JJ to_TO
        consider_VB them_PRP for_IN trials_NNS to_TO improve_VB the_DT clinical_JJ efficacy_NN
        of_IN cancer_NN immunotherapy_NN ._.
      
      
        Conclusions_NNP
        In_IN this_DT study_NN we_PRP showed_VBD that_IN IFNg-inducibility_NNP of_IN MHCII_NNP
        antigens_NNS in_IN weakly_RB inducible_JJ LS_NNP 1034_CD colorectal_NN carcinoma_NN
        cell_NN line_NN can_MD be_VB rescued_VBD by_IN concomitant_NN incubation_NN with_IN PKC_NNP
        agonists_NNS ._. Bryostatin_NNP 1_CD may_MD be_VB considered_VBN for_IN further_JJ
        investigation_NN of_IN IFNg-dependent_NNP MHCII_NNP induction_NN in_IN
        resistant_JJ tumors_NNS 
        in_IN vivo_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Cell_NNP lines_NNS
          Human_JJ tumor_NN cell_NN lines_NNS -_: LS_NNP 1034_CD colorectal_NN carcinoma_NN
          (_( ATCC_NNP Number_NNP :_: CRL-_NNP 2158_CD )_) ,_, SW_NNP 480_CD colorectal_NN adenocarcinoma_NN
          (_( ATCC_NNP Number_NNP :_: CCL-_NNP 228_CD )_) ,_, MSTO-_NNP 211_CD H_NNP biphasic_JJ mesothelioma_NN
          (_( ATCC_NNP Number_NNP :_: CRL-_NNP 2081_CD )_) and_CC HepG_NNP 2_CD hepatocellular_NN
          carcinoma_NN (_( ATCC_NNP Number_NNP :_: HB-_NNP 8065_CD )_) -_: were_VBD purchased_VBN from_IN
          American_NNP Type_NNP Culture_NNP Collection_NNP ._. Cultures_NNP were_VBD routinely_RB
          tested_VBN for_IN Mycoplasma_NNP contamination_NN by_IN Specialty_NNP
          Laboratories_NNPS (_( Santa_NNP Monica_NNP ,_, CA_NNP )_) and_CC were_VBD consistently_RB
          negative_JJ ._.
        
        
          Chemicals_NNS
          Recombinant_NNP human_JJ Interferon_NNP γ_NN 
          1_CD b_SYM ,_, specific_JJ activity_NN 3_CD ·_NN 10_CD 7_CD IU_NNP /_NN mg_NN ,_,
          was_VBD purchased_VBN from_IN InterMune_NNP Pharmaceuticals_NNP ._.
          Staurosporine_NNP and_CC GF_NNP 109203_CD X_NNP were_VBD from_IN Calbiochem_NNP ._. Other_JJ
          chemicals_NNS used_VBN were_VBD phorbol_NN 12_CD -_: myristate_NN 13_CD -_: acetate_NN ,_,
          dimethyl_NN sulfoxide_NN ,_, ethanol_NN ,_, propidium_NN iodide_NN and_CC saponin_NN
          (_( all_DT from_IN Sigma_NNP )_) ._. Fetal_NNP calf_NN serum_NN and_CC RPMI-_NNP 1640_CD culture_NN
          medium_NN supplemented_JJ with_IN 25_CD mM_NN HEPES_NNP were_VBD from_IN Irvine_NNP
          Scientific_NNP ._. Tobramycin_NNP ,_, L-_NNP glutamine_NN and_CC 0_CD ._. 25_CD %_NN porcine_NN
          trypsin_NN -_: 0_CD ._. 53_CD mM_NN EDTA_NNP were_VBD from_IN Abbott_NNP Laboratories_NNPS ,_,
          BioWittaker_NNP and_CC Gibco_NNP correspondingly_RB ._.
        
        
          Antibodies_NNP
          Monoclonal_NNP antibodies_NNS used_VBN in_IN the_DT study_NN were_VBD :_: 1_LS )_) mAb_NN
          against_IN human_JJ HLA-DR_NNP ,_, DP_NNP ,_, DQ_NNP ,_, FITC_NNP conjugate_NN
          (_( anti-_NN MHCII-FITC_NNP )_) ,_, clone_NN Tü_NNP 39_CD ,_, mouse_NN IgG_NNP 2_CD a_SYM ;_: 2_LS )_) mAb_NN
          against_IN human_JJ IFNg_NNP receptor_NN R_NN 1_CD chain_NN ,_, biotin_NN conjugate_NN ,_,
          clone_NN MMHGR-_NNP 1_CD ,_, mouse_NN IgG_NNP 1_CD ;_: 3_LS )_) mAb_NN against_IN human_JJ IFNg_NNP
          receptor_NN R_NN 2_CD chain_NN ,_, biotin_NN conjugate_NN ,_, clone_NN MMHGR-_NNP 2_CD ,_, mouse_NN
          IgG_NNP 1_CD ;_: 4_LS )_) mouse_NN IgG_NNP 2_CD a_DT isotype_NN control_NN mAb_NN ,_, FITC_NNP conjugate_NN
          (_( IgG_NNP 2_CD a-_NN FITC_NNP )_) ;_: 5_LS )_) mouse_NN IgG_NNP 1_CD isotype_NN control_NN mAb_NN ,_, biotin_NN
          conjugate_NN ;_: 6_CD )_) mAb_NN against_IN Rb_NNP protein_NN ,_, FITC_NNP conjugate_NN
          (_( Rb-_NNP FITC_NNP )_) ,_, clone_NN G_NNP 3_CD -_: 245_CD ,_, mouse_NN IgG_NNP 1_CD ;_: 7_CD )_) mouse_NN IgG_NNP 1_CD
          isotype_NN control_NN mAb_NN ,_, FITC_NNP conjugate_NN (_( IgG_NNP 1_CD -_: FITC_NNP )_) ._.
          Streptavidin_NNP ,_, phycoerythrin_NN conjugate_NN (_( SA-PE_NNP )_) and_CC
          Streptavidin_NNP ,_, Alexa_NNP Fluor_NNP ®_NN 488_CD conjugate_NN (_( SA-Alf_NNP 488_CD )_) were_VBD
          from_IN eBioscience_NN and_CC Molecular_NNP Probes_NNP ._.
        
        
          Cell_NNP culture_NN
          Cells_NNP were_VBD propagated_JJ in_IN T_NN 75_CD flasks_NNS in_IN RPMI-_NNP 1640_CD
          medium_NN supplemented_JJ with_IN 25_CD mM_NN HEPES_NNP ,_, 10_CD %_NN fetal_JJ calf_NN
          serum_NN ,_, 200_CD mM_NN L-_NNP glutamine_NN and_CC 40_CD μg_NN /_NN ml_NN Tobramycin_NNP ._. When_WRB
          cells_NNS were_VBD in_IN exponential_NN growth_NN phase_NN ,_, they_PRP were_VBD removed_VBN
          from_IN plastic_NN by_IN trypsinization_NN and_CC seeded_VBN into_IN the_DT wells_NNS
          of_IN 6_CD -_: well_RB trays_NNS (_( 9_CD cm_NN 2_CD /_NN well_RB )_) at_IN a_DT concentration_NN of_IN 3_CD ·_NN 10_CD
          5_CD to_TO 5_CD ·_NN 10_CD 5_CD cells_NNS /_NN 4_CD ml_NN /_NN well_RB ._. When_WRB cell_NN cultures_NNS reached_VBD
          40_CD -_: 60_CD %_NN confluency_NN (_( usually_RB ,_, on_IN the_DT next_JJ day_NN )_) ,_, growth_NN
          medium_NN was_VBD replaced_VBN with_IN 2_CD ml_NN of_IN fresh_JJ medium_NN containing_VBG
          variable_JJ concentrations_NNS of_IN IFNg_NNP ._. Ten_CD minutes_NNS later_RB ,_,
          another_DT 2_CD ml_NN of_IN medium_NN containing_VBG variable_JJ concentrations_NNS
          of_IN PMA_NNP were_VBD added_VBN into_IN the_DT wells_NNS and_CC the_DT incubation_NN
          continued_VBD for_IN the_DT next_JJ 48_CD hr_NN ._. Experiments_NNS involving_VBG
          protein_NN kinase_NN inhibitors_NNS were_VBD performed_VBN in_IN a_DT similar_JJ
          way_NN ,_, except_IN that_DT Staurosporine_NNP and_CC GF_NNP 109203_CD X_NNP were_VBD added_VBN
          first_JJ ,_, and_CC IFNg_NNP (_( or_CC PMA_NNP plus_CC IFNg_NNP )_) were_VBD added_VBN 1_CD hr_NN later_RB ._.
          Staurosporine_NNP and_CC GF_NNP 109203_CD X_NNP were_VBD not_RB washed_VBN away_RB ,_, so_IN the_DT
          cells_NNS were_VBD incubated_JJ with_IN IFNg_NNP +_NN PMA_NNP in_IN the_DT constant_JJ
          presence_NN of_IN inhibitors_NNS ._. In_IN a_DT first_JJ group_NN of_IN experiments_NNS ,_,
          stock_NN solution_NN of_IN PMA_NNP was_VBD prepared_VBN at_IN 1_CD mg_NN /_NN ml_NN in_IN ethanol_NN ,_,
          and_CC the_DT final_JJ concentration_NN of_IN ethanol_NN in_IN culture_NN medium_NN
          was_VBD adjusted_VBN to_TO 10_CD μl_NN /_NN ml_NN (_( 172_CD mM_NN )_) ._. In_IN all_DT subsequent_JJ
          experiments_NNS ,_, stock_NN solution_NN of_IN PMA_NNP was_VBD prepared_VBN at_IN 10_CD
          mg_NN /_NN ml_NN in_IN DMSO_NNP and_CC the_DT final_JJ concentration_NN of_IN DMSO_NNP in_IN
          culture_NN medium_NN was_VBD adjusted_VBN to_TO 1_CD μl_NN /_NN ml_NN ._.
        
        
          Immunofluorescent_NNP staining_VBG of_IN cell_NN surface_NN
          antigens_NNS
          Cellular_NNP monolayers_NNS were_VBD rinsed_JJ 3_CD times_NNS with_IN
          Ca_MD /_NN Mg-free_NNP PBS_NNP and_CC incubated_JJ for_IN 20_CD min_NN at_IN 37_CD °_NN C_NNP in_IN Hanks_NNP '_POS
          balanced_JJ salt_NN solution_NN containing_VBG 0_CD ._. 25_CD %_NN trypsin_NN ,_, 1_CD mM_NN
          EDTA_NNP and_CC 25_CD mM_NN HEPES_NNP ._. Detached_VBN cells_NNS were_VBD washed_VBN twice_RB
          with_IN staining_VBG buffer_NN (_( PBS_NNP containing_VBG 10_CD %_NN FCS_NNP ,_, 0_CD ._. 1_CD %_NN sodium_NN
          azide_NN and_CC 25_CD mM_NN HEPES_NNP ,_, pH_NN 7_CD ._. 4_LS )_) and_CC stained_JJ as_IN described_VBN
          previously_RB [_NN 49_CD ]_NN ._. Briefly_NNP ,_, cells_NNS were_VBD transferred_VBN into_IN
          the_DT wells_NNS of_IN round-bottom_JJ 96_CD -_: well_RB plates_NNS ,_, the_DT plates_NNS were_VBD
          centrifuged_JJ at_IN 200_CD g_SYM for_IN 30_CD seconds_NNS ,_, the_DT supernatant_NN
          removed_VBN by_IN shaking_VBG ,_, and_CC the_DT cell_NN pellets_NNS resuspended_JJ in_IN
          50_CD μl_NN of_IN staining_VBG buffer_NN containing_VBG saturating_VBG
          concentration_NN of_IN anti-_NN MHCII-FITC_NNP ._. After_IN 30_CD -_: min_NN incubation_NN
          at_IN 4_CD °_NN C_NNP ,_, cells_NNS were_VBD washed_VBN twice_RB ,_, resuspended_JJ in_IN staining_VBG
          buffer_NN and_CC kept_VBD on_IN ice_NN before_IN analysis_NN on_IN a_DT flow_NN
          cytometer_NN (_( FACSCalibur_NNP ™_NN ,_, Becton_NNP Dickinson_NNP Immunocytometry_NNP
          Systems_NNPS )_) ._. Immediately_RB before_IN analysis_NN ,_, 1_CD μg_NN /_NN ml_NN propidium_NN
          iodide_NN was_VBD added_VBN to_TO exclude_VB dead_JJ cells_NNS ._. Matching_NNP isotype_NN
          control_NN mAb_NN (_( IgG_NNP 2_CD a-_NN FITC_NNP )_) was_VBD used_VBN at_IN the_DT same_JJ (_( 0_CD ._. 25_CD
          μg_NN /_NN well_RB )_) or_CC a_DT higher_JJR (_( 1_CD ._. 0_CD μg_NN /_NN well_RB )_) concentration_NN as_IN the_DT
          specific_JJ antibody_NN ._. The_DT lack_NN of_IN staining_VBG of_IN controls_NNS
          demonstrated_VBN that_IN non-specific_JJ binding_JJ of_IN IgG_NNP 2_CD a-_NN FITC_NNP to_TO
          PI-negative_NNP cells_NNS was_VBD negligible_JJ in_IN all_DT experimental_JJ
          groups_NNS (_( Fig_NNP 8_CD B_NNP ,_, 8_CD E_NNP ,_, 8_CD H_NNP )_) ._. Staining_NNP for_IN cell_NN surface_NN IFNg_NNP
          receptors_NNS was_VBD performed_VBN similarly_RB ,_, except_IN that_DT cells_NNS were_VBD
          first_JJ incubated_JJ with_IN biotin-conjugated_JJ mAb_NN 's_POS (_( specific_JJ or_CC
          isotype-matched_JJ )_) for_IN 30_CD min_NN ,_, washed_VBD 2_CD times_NNS and_CC then_RB
          stained_JJ with_IN SA-Alf_NNP 488_CD ._. Staining_NNP of_IN fresh_JJ and_CC
          trypsin-treated_JJ monocytes_NNS demonstrated_VBN that_IN epitopes_NNS
          recognized_VBN by_IN the_DT mAb_NN 's_POS against_IN MHCII_NNP ,_, IFNgR_NNP 1_CD and_CC IFNgR_NNP 2_CD
          were_VBD resistant_JJ to_TO 30_CD min_NN digestion_NN with_IN 0_CD ._. 25_CD %_NN
          trypsin_NN ._.
        
        
          Immunofluorescent_NNP staining_VBG of_IN cytoplasmic_JJ
          antigens_NNS
          Cytoplasmic_NNP IFNgR_NNP 1_CD and_CC IFNgR_NNP 2_CD receptor_NN subunits_NNS were_VBD
          detected_VBN by_IN using_VBG a_DT procedure_NN described_VBD for_IN intracellular_NN
          cytokine_NN staining_VBG [_NN 50_CD ]_NN ._. Briefly_NNP ,_, cells_NNS were_VBD fixed_VBN in_IN
          ice-cold_JJ 4_CD %_NN formaldehyde_NN for_IN 5_CD min_NN ,_, washed_VBD 2_CD times_NNS ,_,
          permeabilized_JJ in_IN staining_VBG buffer_NN containing_VBG 0_CD ._. 2_CD %_NN saponin_NN
          for_IN 60_CD min_NN at_IN 4_CD °_NN C_NNP ,_, incubated_JJ with_IN biotin-conjugated_JJ mAb_NN 's_POS
          (_( specific_JJ or_CC isotype-matched_JJ )_) for_IN 30_CD min_NN ,_, washed_VBD 2_CD times_NNS ,_,
          incubated_JJ with_IN SA-PE_NNP and_CC washed_VBN again_RB (_( saponin_NN was_VBD
          present_JJ in_IN staining_VBG buffer_NN at_IN all_DT times_NNS )_) ._. After_IN the_DT final_JJ
          wash_NN ,_, cells_NNS were_VBD resuspended_JJ in_IN buffer_NN without_IN saponin_NN
          and_CC kept_VBD on_IN ice_NN until_IN analysis_NN ._. Monocytes_NNP expressing_VBG high_JJ
          levels_NNS of_IN IFNgR_NNP 1_CD and_CC IFNgR_NNP 2_CD receptor_NN subunits_NNS served_VBD as_IN a_DT
          positive_JJ control_NN ._. Expression_NNP levels_NNS of_IN Rb_NNP protein_NN was_VBD
          measured_VBN using_VBG a_DT procedure_NN described_VBD elsewhere_RB [_NN 51_CD ]_NN
          ._.
        
        
          Flow_NNP cytometry_NN
          Fluorescent_NNP emission_NN of_IN FITC_NNP and_CC Alexa_NNP Fluor_NNP ®_NN 488_CD was_VBD
          collected_VBN on_IN the_DT FL_NNP 1_CD detector_NN (_( 530_CD ±_NN 30_CD nm_NN ,_, log_VB mode_NN )_) and_CC
          fluorescence_NN of_IN PI-stained_NNP DNA_NNP was_VBD collected_VBN on_IN the_DT FL_NNP 3_CD
          detector_NN (_( >_NN 650_CD nm_NN ,_, log_VB mode_NN )_) ._. Incubation_NNP of_IN tumor_NN
          cells_NNS with_IN PMA_NNP or_CC staurosporine_NN dramatically_RB increased_VBD
          cell-to-cell_JJ adherence_NN and_CC number_NN of_IN cell_NN clumps_NNS ._. To_TO deal_VB
          with_IN this_DT problem_NN ,_, the_DT FL_NNP 2_CD detector_NN (_( 585_CD ±_NN 42_CD nm_NN ,_, linear_JJ
          mode_NN )_) was_VBD used_VBN to_TO measure_VB area_NN and_CC width_NN of_IN electronic_JJ
          pulses_NNS ._. PMT_NNP voltage_NN of_IN the_DT FL_NNP 2_CD detector_NN was_VBD set_VBN high_JJ
          enough_RB to_TO minimize_VB the_DT number_NN of_IN FL_NNP 2_CD -_: width_NN events_NNS
          appearing_VBG in_IN channel_NN 1_CD ._. Regions_NNP R_NNP 1_CD ,_, R_NN 2_CD and_CC R_NN 3_CD were_VBD drawn_VBN
          to_TO exclude_VB debris_NN (_( Fig_NNP 8_CD G_NNP )_) ,_, dead_JJ cells_NNS (_( Fig_NNP 8_CD A_DT ,_, 8_CD B_NNP ,_, 8_CD C_NNP )_) and_CC
          cellular_JJ aggregates_NNS (_( Fig_NNP 8_CD D_NNP ,_, 8_CD E_NNP ,_, 8_CD F_NN )_) ._. Acquisition_NNP was_VBD
          stopped_VBN when_WRB at_IN least_JJS 10_CD ,_, 000_CD events_NNS had_VBD passed_VBN R_NN 1_CD &_CC
          R_NN 2_CD &_CC R_NN 3_CD logical_JJ gate_NN (_( Figure_NN 8_CD H_NNP )_) ._. List_NN mode_NN data_NNS
          files_NNS were_VBD transferred_VBN to_TO a_DT Windows-based_NNP computer_NN for_IN
          off-line_JJ analysis_NN ._. Data_NNP were_VBD gated_JJ and_CC the_DT median_JJ values_NNS
          of_IN fluorescence_NN peaks_NNS were_VBD computed_JJ by_IN using_VBG FCSExpress_NNP
          software_NN written_VBN by_IN David_NNP Novo_NNP
          http_NN :_: /_NN /_NN www_NN ._. denovosoftware_NN ._. com_NN ._.
        
        
          Data_NNP Analysis_NNP
          Total_JJ fluorescence_NN of_IN cells_NNS stained_JJ with_IN MHCII-FITC_NNP
          antibody_NN can_MD be_VB divided_VBN into_IN 3_CD sources_NNS :_: (_( 1_LS )_) fluorescence_NN
          caused_VBN by_IN specific_JJ binding_JJ of_IN MHCII-FITC_NNP ,_, (_( 2_LS )_)
          fluorescence_NN of_IN MHCII-FITC_NNP bound_VBN to_TO cells_NNS
          non-specifically_JJ and_CC (_( 3_LS )_) autofluorescence_NN of_IN
          intracellular_NN molecules_NNS such_JJ as_IN NAD_NNP (_( P_NN )_) H_NNP ._. An_DT experiment_NN
          performed_VBN to_TO assess_VB contribution_NN of_IN each_DT of_IN the_DT three_CD
          sources_NNS demonstrated_VBN that_IN :_: (_( 1_LS )_) non-specific_JJ binding_JJ of_IN
          IgG_NNP 2_CD a-_NN FITC_NNP was_VBD negligible_JJ in_IN all_DT experimental_JJ groups_NNS (_( Fig_NNP
          8_CD H_NNP )_) ;_: (_( 2_LS )_) tumor_NN cells_NNS incubated_JJ with_IN PMA_NNP alone_RB did_VBD not_RB
          bind_NN anti-_NN MHCII_NNP mAb_NN above_IN the_DT level_NN of_IN isotype_NN control_NN
          and_CC (_( 3_LS )_) tumor_NN cells_NNS incubated_JJ with_IN PMA_NNP (_( or_CC with_IN PMA_NNP +_NN IFNg_NNP )_)
          demonstrated_VBN 1_CD ._. 2_CD -_: 1_CD ._. 4_LS fold_VB increase_NN in_IN autofluorescence_NN ._.
          In_IN order_NN to_TO correct_VB for_IN non-specific_JJ increase_NN in_IN
          autofluorescence_NN ,_, "_'' brightness_NNS "_'' of_IN cells_NNS treated_VBN with_IN PMA_NNP
          alone_RB (_( Table_NNP 1_CD ,_, column_NN 1_LS )_) was_VBD subtracted_VBN from_IN
          "_'' brightness_NNS "_'' of_IN cells_NNS treated_VBN with_IN PMA_NNP +_NN IFNg_NNP (_( Table_NNP 1_CD ,_,
          columns_NNS 2_CD -_: 4_LS )_) ,_, e_SYM ._. g_SYM ._. ,_, group_NN 05_CD a_DT value_NN was_VBD subtracted_VBN from_IN
          values_NNS of_IN group_NN 11_CD a_DT ,_, 17_CD a_DT and_NN 23_CD a_DT ,_, etc_FW ._. All_DT statistics_NNS
          were_VBD calculated_VBN using_VBG these_DT corrected_VBN values_NNS that_WDT
          represent_VBP distances_NNS (_( channel_NN shifts_NNS )_) between_IN median_NN of_IN
          fluorescence_NN peaks_NNS ._. The_DT additional_JJ file_NN
          "_'' ANOVA_NNP ._. xls_NNS "_'' contains_VBZ both_DT raw_JJ and_CC corrected_VBN fluorescence_NN
          values_NNS used_VBN to_TO perform_VB the_DT analysis_NN ._.
          Additional_JJ File_NNP 1_CD
          Induction_NNP of_IN MHCII_NNP molecules_NNS is_VBZ measured_VBN as_IN the_DT
          distance_NN between_IN the_DT median_NN of_IN the_DT experiment_NN histogram_NN
          and_CC the_DT median_NN of_IN the_DT negative_JJ control_NN histogram_NN ._. This_DT
          file_NN contains_VBZ data_NNS and_CC charts_NNS for_IN the_DT majority_NN of_IN the_DT
          subjects_NNS used_VBN in_IN the_DT current_JJ experiment_NN
          Click_NNP here_RB for_IN file_NN
        
      
      
        Note_VB added_VBN in_IN proof_NN
        While_IN the_DT manuscript_NN was_VBD under_IN review_NN ,_, results_NNS of_IN a_DT
        clinical_JJ trial_NN had_VBD been_VBN published_VBN showing_VBG that_IN a_DT systemic_JJ
        combination_NN treatment_NN with_IN IFNg_NNP and_CC GM-CSF_NNP for_IN as_RB long_RB as_IN
        9_CD -_: weeks_NNS failed_VBD to_TO induce_VB MHCII_NNP on_IN tumor_NN cells_NNS in_IN 9_CD out_IN of_IN
        15_CD hepatocellular_NN carcinoma_NN patients_NNS ._. However_RB ,_, those_DT 6_CD
        patients_NNS with_IN inducible_JJ MHCII_NNP on_IN hepatoma_NN cells_NNS had_VBD better_RBR
        median_JJ survival_NN as_IN compared_VBN to_TO MHCII_NNP negative_JJ cases_NNS (_( p_NN <_NN
        0_CD ._. 0001_CD )_) [_NN 52_CD ]_NN ._.
      
      
        List_NN of_IN abbreviations_NNS used_VBN
        class_NN II_NNP transactivator_NN CIITA_NNP
        dimethyl_NN sulfoxide_NN DMSO_NNP
        fetal_JJ calf_NN serum_NN FCS_NNP
        fluorescein_NN isotiocyanate_NN FITC_NNP
        interferon-gamma_JJ IFNg_NNP
        interferon-gamma_JJ receptor_NN IFNgR_NNP
        interferon-gamma_JJ receptor_NN alpha-chain_JJ IFNgR_NNP 1_CD
        interferon-gamma_JJ receptor_NN beta-chain_JJ IFNgR_NNP 2_CD
        granulocyte-macrophage_JJ colony-stimulating_JJ factor_NN
        GM-CSF_NNP
        Janus_NNP kinase_NN JAK_NNP
        major_JJ histocompatibility_NN complex_JJ class_NN II_NNP antigens_NNS
        MHCII_NNP
        mitogen-activated_JJ protein_NN kinase_NN MAPK_NNP
        monoclonal_NN antibody_NN mAb_NN
        phorbol_NN 12_CD -_: myristate_NN 13_CD -_: acetate_NN PMA_NNP
        propidium_NN iodide_NN PI_NNP
        protein_NN kinase_NN c_SYM PKC_NNP
        signal_NN transducer_NN and_CC activator_NN of_IN transcription_NN 1_CD
        STAT_NNP 1_CD
        the_DT retinoblastoma_NN tumor_NN suppressor_NN protein_NN Rb_NNP
      
    
  
